
|Articles|October 8, 2020 (Updated: March 30, 2021)
QUIZ: The ALEX Study for ALK+ Non-Small Cell Lung Cancer
Author(s)Hannah Slater
In our lung cancer quiz, you’ll get to test your knowledge on the ALEX study.
Advertisement
What characteristics of alectinib therapy made it a viable treatment option versus crizotinib.
a. It has greater potency/selectivity for ALK.
b. It is a central nervous system penetrant.
c. It has the ability to target resistance mutations.
d. All of the above
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Related Content
Advertisement


Quiz: The Phase 3 ALESIA Study for ALK-Positive Non-Small Cell Lung Cancer
Published: | Updated:


Quiz: Best Second-Line Tx for Metastatic Lung SCC and Crohn Disease?
Published: | Updated:

Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Removes Black Box Warning for Breast Cancer and Other Indications on HRT Products
2
FDA Accepts NDA for Iberdomide Combination in R/R Multiple Myeloma
3
Where Does KEYNOTE-B96 Regimen Fit in Pretreated Ovarian Cancer?
4
How Tolerable is Pembrolizumab/Paclitaxel/Bevacizumab in PROC?
5





































